Rich-Vicks ibuprofen/pseudoephedrine patent ruled invalid by circuit court.
This article was originally published in The Tan Sheet
Executive Summary
RICH-VICKS IBUPROFEN/PSEUDOEPHEDRINE PATENT NOT VALID, a Wilmington, Del. federal appeals court ruled recently, quashing the Procter & Gamble division's hopes of having federal Judge Sue Robinson's post-trial judgment in favor of the defendants, Pharmacia & Upjohn and McNeil, overturned. The ibuprofen/pseudoephedrine combination patent was deemed not enforceable by both courts on the basis that the cough/cold product formula is "obvious," or easily derived by anyone of "ordinary skill in the art."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning